On the Pharmacology of Farnesoid X Receptor Agonists: Give me an "A", Like in "Acid"

The Farnesoid X Receptor (FXR) has recently moved into the spotlight through the release of clinical data using Obeticholic Acid, an FXR agonist, that demonstrated effectiveness of this bile acid-like drug in patients with Primary Biliary Cirrhosis and Non-alcoholic Steatohepatitis (NASH). FXR holds the promise to become an attractive drug target for various conditions, from Non-alcoholic Fatty Liver Disease (NAFLD), NASH, liver cirrhosis, portal hypertension and a variety of cholestatic disorders to intestinal diseases including inflammatory bowel disease and bile acid diarrhea. Despite the wide therapeutic potential, surprisingly little is known about the pharmacology, pharmacokinetics and tissue distribution properties of drugs targeting FXR. Are tissue specific FXR agonists preferable for different indications, or might one type of ligand fit all purposes? This review aims to summarize the sparse data which are available on this clinically and pharmacologically relevant topic and provides a mechanistic model for understanding tissue-specific effects in vivo.

[1]  F. Bäckhed,et al.  Microbiota-induced obesity requires farnesoid X receptor , 2016, Gut.

[2]  R. Copeland.  The drug–target residence time model: a 10-year retrospective , 2015, Nature Reviews Drug Discovery.

[3]  William H. Bisson,et al.  Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction , 2015, Nature Communications.

[4]  U. Deuschle,et al.  The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine‐rich glycoprotein , 2015, International journal of cancer.

[5]  K. Lindor,et al.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.

[6]  B. Neuschwander‐Tetri,et al.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial , 2015, The Lancet.

[7]  D. Brenner,et al.  Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance , 2015, Nature Medicine.

[8]  R. Pellicciari,et al.  Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation. , 2014, Current topics in medicinal chemistry.

[9]  R. Pellicciari,et al.  Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands. , 2014, Current topics in medicinal chemistry.

[10]  L. Adorini,et al.  Semisynthetic Bile Acid FXR and TGR5 Agonists: Physicochemical Properties, Pharmacokinetics, and Metabolism in the Rat , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[11]  V. Tremaroli,et al.  FXR is a molecular target for the effects of vertical sleeve gastrectomy , 2014, Nature.

[12]  A. McIntosh,et al.  The human liver fatty acid binding protein T94A variant alters the structure, stability, and interaction with fibrates. , 2013, Biochemistry.

[13]  A. McIntosh,et al.  Liver‐type fatty acid binding protein interacts with hepatocyte nuclear factor 4α , 2013, FEBS letters.

[14]  J. Muntané,et al.  Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. , 2013, Biochemical pharmacology.

[15]  James B. Mitchell,et al.  Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity , 2013, Nature Communications.

[16]  L. Agellon,et al.  Transport and biological activities of bile acids. , 2013, The international journal of biochemistry & cell biology.

[17]  J. Boyer,et al.  Bile formation and secretion. , 2013, Comprehensive Physiology.

[18]  M. Miyazaki,et al.  Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice , 2012, Journal of Pharmacology and Experimental Therapeutics.

[19]  B. M. Forman,et al.  Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice , 2012, Hepatology.

[20]  F. Bäckhed,et al.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.

[21]  Frances M. Sladek,et al.  What are nuclear receptor ligands? , 2011, Molecular and Cellular Endocrinology.

[22]  P. Siersema,et al.  Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease , 2011, Gut.

[23]  K. Faber,et al.  Unconjugated bile salts shuttle through hepatocyte peroxisomes for taurine conjugation , 2010, Hepatology.

[24]  U. Beuers,et al.  The biliary HCO3− umbrella: A unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies , 2010, Hepatology.

[25]  U. Deuschle,et al.  Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. , 2010, Bioorganic & medicinal chemistry letters.

[26]  Yanqiao Zhang,et al.  Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity. , 2010, Molecular endocrinology.

[27]  M. Evans,et al.  Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. , 2010, Journal of medicinal chemistry.

[28]  E. Distrutti,et al.  The Bile Acid Receptor FXR Is a Modulator of Intestinal Innate Immunity1 , 2009, The Journal of Immunology.

[29]  B. M. Forman,et al.  Farnesoid X receptor alleviates age‐related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription , 2009, Hepatology.

[30]  Songwen Zhang,et al.  Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[31]  H. R. Payne,et al.  L-FABP directly interacts with PPAR&agr; in cultured primary hepatocytes , 2009, Journal of Lipid Research.

[32]  S. Fiorucci,et al.  Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages. , 2009, Biochimica et biophysica acta.

[33]  Eugene Bolotin,et al.  Identification of an Endogenous Ligand Bound to a Native Orphan Nuclear Receptor , 2009, PloS one.

[34]  E. Distrutti,et al.  Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. , 2009, World journal of gastroenterology.

[35]  C. Huard,et al.  A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[36]  Stefan Westin,et al.  Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). , 2009, Journal of medicinal chemistry.

[37]  B. M. Forman,et al.  Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response , 2008, Hepatology.

[38]  A. Hofmann,et al.  Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics , 2008, Cellular and Molecular Life Sciences.

[39]  S. Asano,et al.  Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. , 2008, Acta histochemica.

[40]  S. Khorasanizadeh,et al.  Identification of heme as the ligand for the orphan nuclear receptors REV-ERBα and REV-ERBβ , 2007, Nature Structural &Molecular Biology.

[41]  M. Fornerod,et al.  The inner nuclear envelope as a transcription factor resting place , 2007, EMBO reports.

[42]  D. Moore,et al.  Alterations in xenobiotic metabolism in the long‐lived Little mice , 2007, Aging cell.

[43]  J. Auwerx,et al.  In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. , 2007, Molecular endocrinology.

[44]  W. Alrefai,et al.  Bile Acid Transporters: Structure, Function, Regulation and Pathophysiological Implications , 2007, Pharmaceutical Research.

[45]  C. Muller,et al.  Nuclear receptors in human immune cells: expression and correlations. , 2007, Molecular immunology.

[46]  S. Li,et al.  Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation* , 2006, Journal of Biological Chemistry.

[47]  B. Brewer,et al.  Effects of FXR in foam-cell formation and atherosclerosis development. , 2006, Biochimica et biophysica acta.

[48]  S. Fiorucci,et al.  The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo , 2006, Molecular Pharmacology.

[49]  R. Evans,et al.  Anatomical Profiling of Nuclear Receptor Expression Reveals a Hierarchical Transcriptional Network , 2006, Cell.

[50]  Folkert Kuipers,et al.  The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* , 2006, Journal of Biological Chemistry.

[51]  D. Moore,et al.  Nuclear Receptor-Dependent Bile Acid Signaling Is Required for Normal Liver Regeneration , 2006, Science.

[52]  Ke Ma,et al.  Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.

[53]  S. Kliewer,et al.  Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Simon C Watkins,et al.  Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells , 2006, Circulation research.

[55]  Timothy M Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[56]  K. Takagaki,et al.  Ileal Bile Acid-binding Protein, Functionally Associated with the Farnesoid X Receptor or the Ileal Bile Acid Transporter, Regulates Bile Acid Activity in the Small Intestine* , 2005, Journal of Biological Chemistry.

[57]  A. McIntosh,et al.  Liver fatty-acid-binding protein (L-FABP) gene ablation alters liver bile acid metabolism in male mice. , 2005, The Biochemical journal.

[58]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[59]  T. Warner,et al.  Expression and activation of the farnesoid X receptor in the vasculature. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[60]  S. Kliewer,et al.  Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. , 2003, Genes & development.

[61]  M. Bowman,et al.  A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. , 2003, Molecular cell.

[62]  R. Evans,et al.  Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. , 2003, Organic & biomolecular chemistry.

[63]  Jasmine Chen,et al.  Identification of Gene-selective Modulators of the Bile Acid Receptor FXR* , 2003, The Journal of Biological Chemistry.

[64]  Heidi R. Kast-Woelbern,et al.  Natural Structural Variants of the Nuclear Receptor Farnesoid X Receptor Affect Transcriptional Activation* , 2003, The Journal of Biological Chemistry.

[65]  T. Willson,et al.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. , 2002, Journal of medicinal chemistry.

[66]  M. Makishima,et al.  Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.

[67]  L. Moore,et al.  Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.

[68]  P. Edwards,et al.  Identification of the DNA Binding Specificity and Potential Target Genes for the Farnesoid X-activated Receptor* , 2000, The Journal of Biological Chemistry.

[69]  T. Willson,et al.  Identification of a Bile Acid-responsive Element in the Human Ileal Bile Acid-binding Protein Gene , 1999, The Journal of Biological Chemistry.

[70]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[71]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[72]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[73]  W. Wahli,et al.  Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. , 1997, Molecular endocrinology.

[74]  D. Wilton,et al.  The binding of cholesterol and bile salts to recombinant rat liver fatty acid-binding protein. , 1996, Biochemical Journal.

[75]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[76]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[77]  P. Meier.  Molecular mechanisms of hepatic bile salt transport from sinusoidal blood into bile. , 1995, The American journal of physiology.

[78]  Jasmine Chen,et al.  Identification of a nuclear receptor that is activated by farnesol metabolites , 1995, Cell.

[79]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[80]  J. Chipman,et al.  Fluorescent choleretic and cholestatic bile salts take different paths across the hepatocyte: transcytosis of glycolithocholate leads to an extensive redistribution of annexin II , 1994, The Journal of cell biology.

[81]  J. Crawford,et al.  Role of bile salt hydrophobicity in hepatic microtubule-dependent bile salt secretion. , 1994, Journal of lipid research.

[82]  P. Meier,et al.  Hepatocellular transport of bile acids. Evidence for distinct subcellular localizations of electrogenic and ATP-dependent taurocholate transport in rat hepatocytes. , 1994, The Journal of biological chemistry.

[83]  B. Bouscarel,et al.  Comparative binding of bile acids to serum lipoproteins and albumin. , 1993, Journal of lipid research.

[84]  J. Crawford,et al.  Microtubule‐dependent transport of bile salts through hepatocytes: Cholic vs. taurocholic acid , 1993, Hepatology.

[85]  F. Suchy.  Hepatocellular Transport of Bile Acids , 1993, Seminars in liver disease.

[86]  J. Gustafsson,et al.  Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Grippo,et al.  9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα , 1992, Nature.

[88]  J. Boyer,et al.  Tubulovesicular transcytotic pathway in isolated rat hepatocyte couplets in culture. Effect of colchicine and taurocholate. , 1988, Gastroenterology.

[89]  V. Giguère,et al.  Identification of a receptor for the morphogen retinoic acid , 1987, Nature.

[90]  Y. Sugiyama,et al.  3 alpha-hydroxysteroid dehydrogenase activity of the Y' bile acid binders in rat liver cytosol. Identification, kinetics, and physiologic significance. , 1987, The Journal of clinical investigation.

[91]  R. Evans,et al.  The c-erb-A gene encodes a thyroid hormone receptor , 1986, Nature.

[92]  H. Beug,et al.  The c-erb-A protein is a high-affinity receptor for thyroid hormone , 1986, Nature.

[93]  G. Fleischner,et al.  The identity of glutathione S-transferase B with ligandin, a major binding protein of liver. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[94]  C. Kremoser,et al.  Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities. , 2014, Current topics in medicinal chemistry.

[95]  M. Anwer,et al.  Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters , 2013, Pflügers Archiv - European Journal of Physiology.

[96]  P. Dawson.  Role of the intestinal bile acid transporters in bile acid and drug disposition. , 2011, Handbook of experimental pharmacology.

[97]  Dennis A. Smith.  Metabolism, pharmacokinetics and toxicity of functional groups : impact of chemical building blocks on ADMET , 2010 .

[98]  A. Moschetta,et al.  Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio. , 2009, Frontiers in bioscience.

[99]  S. Khorasanizadeh,et al.  Identification of heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REV-ERBbeta. , 2007, Nature structural & molecular biology.

[100]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[101]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.

[102]  B. Spiegelman,et al.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. , 1995, Cell.

[103]  ON THE METABOLISM , 2022 .